Single-center prospective observational study investigating the impact of beta1 adrenergic receptor and its auto-antibody on responsiveness of beta-blocker in heart failure therapy.

Single-center prospective observational study investigating the impact of beta1 adrenergic receptor and its auto-antibody on responsiveness of beta-blocker in heart failure therapy. - Pharmacology research on responsiveness of beta-blocker.

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000059234

Enrollment

100

Registered

2025-09-29

Start date

2024-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

heart failure

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who are 18 years of age or older at the time of consent. Patients diagnosed heart failure newly introduced to beta-blocker as treatment for heart failure. Patients who have been fully informed of the study and who have given written consent of their own free will.

Exclusion criteria

Exclusion criteria: Patients with significantly poor medication adherence Patients with advanced cancer Patients with a history of autoimmune disease. Patients deemed inappropriate by the attending physician, etc.

Design outcomes

Primary

Measure	Time frame
Heart disease-related death Cardiovascular events Hospitalization of worsening heart failure	—

Countries

Japan

Contacts

Public ContactMasaki Kawata

Hamamatsu University School of Medicine Hospital Pharmacy

k.masaki@hama-med.ac.jp053-435-2767

Outcome results